NOVADIP Biosciences S.A.

NOVADIP Biosciences S.A.

is a clinical-stage biopharmaceutical company based in Mont-Saint-Guibert, Belgium, founded in 2013. The company focuses on developing regenerative tissue products aimed at accelerating the healing of large bone defects, bone non-union, and spine fusion. Their mission is to create innovative solutions for patients with significant unmet medical needs, particularly those with limited treatment options. The company utilizes its proprietary 3M3 tissue regeneration technology platform, which employs adipose-derived stem cells to deliver growth factors and miRNAs that mimic natural physiology for tissue regeneration. NOVADIP is currently advancing two lead products in clinical trials: NVD-003, an autologous cell-based therapy for bone non-union and pediatric orthopedic conditions, and NVD-X3, an allogeneic bone grafting material designed for trauma surgery and spine fusion. With a dedicated team of approximately 45 staff members, NOVADIP is committed to improving patient outcomes in regenerative medicine.